Scholarlink

<p>During the last decade, diagnosis and therapy of prostate cancer have been accomplished with clear evidence of enhanced survival. Improved diagnostic capabilities, particularly radiolabeled PSMA PET/CT approaches benefit from reduced unnecessary biopsies and more accuracy. The advantage of visualization of the abnormalities prior to therapeutic procedures is clarifying these locations specifically in order to targeting therapy applying the theranostic principle. Targeted therapy with high efficacy and minimal damage has emerged as very promising advancement in nuclear medicine. Recently, radiolabeled PSMA-617 and other derivatives have shown considerable improvements in the management of advanced-stage PSMA–positive mCRPC. This manuscript attempts to summarize the most recent advancements in the diagnosis and treatment of prostate cancer in nuclear medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A review of PSMA-based radiopharmaceuticals for diagnosis and therapy of prostate cancer

  • 期刊论文

  • 发表日期：

    2025年9月25日

查看全文
  • Abolfazl Farbod,
  • Saeed Farzanehfar,
  • Mohsen Beheshti,
  • Ebrahim S. Delpassand,
  • Mohammad Jawed Hashmi,
  • Ayuob Aghanejad,
  • Elisabeth Eppard,
  • Nasim Vahidfar

摘要

During the last decade, diagnosis and therapy of prostate cancer have been accomplished with clear evidence of enhanced survival. Improved diagnostic capabilities, particularly radiolabeled PSMA PET/CT approaches benefit from reduced unnecessary biopsies and more accuracy. The advantage of visualization of the abnormalities prior to therapeutic procedures is clarifying these locations specifically in order to targeting therapy applying the theranostic principle. Targeted therapy with high efficacy and minimal damage has emerged as very promising advancement in nuclear medicine. Recently, radiolabeled PSMA-617 and other derivatives have shown considerable improvements in the management of advanced-stage PSMA–positive mCRPC. This manuscript attempts to summarize the most recent advancements in the diagnosis and treatment of prostate cancer in nuclear medicine.